These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16885839)

  • 1. [Sirolimus-induced onychopathy in renal transplant recipients].
    Mahé E; Morelon E; Lechaton S; Kreis H; De Prost Y; Bodemer C
    Ann Dermatol Venereol; 2006; 133(6-7):531-5. PubMed ID: 16885839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy.
    Mahé E; Morelon E; Lechaton S; Sang KH; Mansouri R; Ducasse MF; Mamzer-Bruneel MF; de Prost Y; Kreis H; Bodemer C
    Transplantation; 2005 Feb; 79(4):476-82. PubMed ID: 15729175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study.
    Özcan D; Seçkin D; Ada S; Haberal M
    Clin Transplant; 2013; 27(5):742-8. PubMed ID: 23991694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs.
    Renders L; Steinbach R; Valerius T; Schöcklmann HO; Kunzendorf U
    Kidney Blood Press Res; 2004; 27(3):181-5. PubMed ID: 15256815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study.
    Troppmann C; Pierce JL; Gandhi MM; Gallay BJ; McVicar JP; Perez RV
    Transplantation; 2003 Jul; 76(2):426-9. PubMed ID: 12883205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late introduction of sirolimus induces anemia in renal transplant recipients.
    Thaunat O; Beaumont C; Lechaton S; Kreis H; Morelon E
    Transplantation; 2007 May; 83(9):1283; author reply 1284. PubMed ID: 17496550
    [No Abstract]   [Full Text] [Related]  

  • 8. Sirolimus Associated with Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial.
    Kojima CA; Nga HS; Takase HM; Bravin AM; Martinez Garcia MFF; Garcia PD; Contti MM; de Andrade LGM
    Exp Clin Transplant; 2018 Jun; 16(3):301-306. PubMed ID: 28836934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
    Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B
    Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced nail abnormalities.
    Piraccini BM; Iorizzo M; Antonucci A; Tosti A
    Expert Opin Drug Saf; 2004 Jan; 3(1):57-65. PubMed ID: 14680462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus: a switch option for mycophenolate mofetil-induced leukopenia in renal transplant recipients.
    Shin BC; Chung JH; Kim HL
    Transplant Proc; 2013 Oct; 45(8):2968-9. PubMed ID: 24157014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angioedema in renal transplant recipients on sirolimus.
    Mahé E; Morelon E; Lechaton S; Kreis H; de Prost Y; Bodemer C
    Dermatology; 2007; 214(3):205-9. PubMed ID: 17377381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
    Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
    J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.